Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
News|Articles|November 16, 2015
EMA Executive Director Guido Rasi Takes Office
Author(s)Pharmaceutical Technology Editors
The new executive director of the European Medicines Agency begins appointment.
Advertisement
Professor Guido Rasi has begun his five-year appointment as executive director of the European Medicines Agency (EMA). Rasi was nominated for the position on Oct. 1, 2015 and was appointed Oct. 13, 2015. Rasi served previously as executive director of EMA from November 2011–November 2014.
“I am very happy to be back at the helm of the Agency,” Rasi said in a
Professor Rasi previously served as EMA’s principal adviser in charge of strategy and was the director-general of the Italian Medicines Agency from 2008 to
2011. He also worked at the Institute for Experimental Medicine of the National Research Council, Italy and was the director of the Institute of Molecular Medicine of the National Research Council in Rome. Professor Rasi holds a degree in medicine and surgery, with specializations in internal medicine, allergology, and clinical immunology from the University of Rome.
Source:
Advertisement
Related to this article
The FDA approves remibrutinib for symptomatic dermographism, the first such therapy, extending an oral BTK inhibitor label via the Phase III RemIND trial.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
Advertisement
Advertisement